Company / Financials
AMICUS THERAPEUTICS, INC. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$634.2M
FY2025 · +20.0% YoY
Net Income
-$27.1M
FY2025 · +51.7% YoY
Profit Margin
-4.3%
FY2025 · net income / revenue
ROE
-9.9%
FY2025 · return on equity
Total Assets
$949.9M
FY2025
Total Debt
$392.7M
1.43x debt/equity
Equity
$274.2M
FY2025
ROA
-2.9%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$634.2M+20.0% YoYNet Income HistoryProfit after all expenses and taxes-$27.1M+51.7% YoYGross Profit HistoryRevenue minus cost of goods sold$561.3M+18.1% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$72.9M+37.8% YoYOperating Income HistoryProfit from core business operations before interest and taxes$32.8M+31.8% YoYSG&A Expense HistorySelling, general, and administrative expenses$383.5M+18.6% YoYR&D Expense HistoryResearch and development spending$135.8M+24.2% YoYInterest Expense HistoryCost of borrowing and debt obligations$50.1MIncome Tax HistoryTotal income tax expense$27.3M-0.2% YoYEPS (Basic) HistoryBasic earnings per share-$0.51+37.8% YoY